District Court, District of Columbia May 28, 2004, CIV.A. 02-1939(RMU) (Jerome Stevens Pharmaceuticals, Inc. v. Food & Drug Administration)

Also known as

United States · · · 28-05-2004

MEMORANDUM OPINION

URBINA, District Judge.

GRANTING THE DEFENDANTS’ Motion to Dismiss

I. INTRODUCTION

Plaintiff Jerome Stevens Pharmaceuticals, Inc. (“Jerome”) is a small company that manufactures levothyroxine sodium (“LS”) tablets under the name of Uni-throid. Jerome brings suit against the Food and Drug Administration (“FDA”), Department of Health and Human Services (“HHS”), and United States (collectively, “the defendants”

1

) alleging violations of the Federal Tort Claims Act (“FTCA”), 28 U.S.C. §§ 1346(b), 2671-2680; Administrative Procedure Act (“APA”), 5 U.S.C. §§ 701

et seq.;

and Fifth Amendment to the Constitution. The defendants moved to dismiss Jerome’s claims pursuant to Federal Rules of Civil Procedure 12(b)(1) and (6). Because the

*47

court lacks subject-matter jurisdiction under the FTCA, the APA and the Constitution, the court grants the defendants’ motion to dismiss.

II. BACKGROUND

A. Background

Since the 1950s, physicians have prescribed LS tablets for the treatment of thyroid diseases. Compl. ¶ 8. In August 1997, however, FDA issued a notice that new information had shown significant stability and potency problems with currently marketed LS products, and that this lack of stability and consistent potency had the potential to cause serious public-health consequences.

Id.

¶¶ 15-16 (citing 62 Fed. Reg. 43535 (Aug. 14, 1997)). Accordingly, notwithstanding the history of LS use, FDA announced that orally administered LS products were “new drugs,” and that manufacturers wishing to continue marketing LS products would have to submit New Drug Applications (“NDAs”) for FDA approval by August 14, 2000 or be subject to adverse regulatory action.

Id.

¶¶ 14,17.

FDA initially set a deadline of August 14, 2000 for the NDA approval date.

Id.

¶ 17. In April 2000, however, a few months prior to the deadline, FDA extended the deadline by one year, to August 14, 2001.

Id.

¶ 29 (citing 65 Fed. Reg. 24488 (Apr. 26, 2000)).

Read the full text

This document is published by courtlistener.com.

Moonlit adds the citation network, article-level links and cross-references, which are available to search for free.